Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Deferred Tax Liability (2016 - 2025)

Sanofi's Non-Current Deferred Tax Liability history spans 9 years, with the latest figure at $1.9 billion for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 16.21% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, down 16.21%, while the annual FY2025 figure was $1.9 billion, 19.71% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $1.9 billion at Sanofi, down from $2.3 billion in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $2.3 billion in Q4 2024 and bottomed at $1.8 billion in Q4 2021.
  • The 5-year median for Non-Current Deferred Tax Liability is $1.9 billion (2025), against an average of $2.0 billion.
  • The largest annual shift saw Non-Current Deferred Tax Liability grew 15.84% in 2024 before it dropped 16.21% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2021, then grew by 1.54% to $1.9 billion in 2022, then grew by 6.38% to $2.0 billion in 2023, then grew by 15.84% to $2.3 billion in 2024, then decreased by 16.21% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Non-Current Deferred Tax Liability are $1.9 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.0 billion (Q4 2023).